Monica Wallter
CEO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 737 070922
Email: monica.wallter@liddspharma.com
Anja Peters
CFO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 733 260000
Email: anja.peters@liddspharma.com
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2020-12-22
LIDDS has decided to apply for listing of the company’s shares on Nasdaq Stockholm Main Market in 2021 - 2020-12-18 Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot
- 2020-12-15 LIDDS AB (publ) announces the appointment of Nina Herne as CEO
- 2020-11-19
LIDDS Delårsrapport januari – september 2020
- 2020-11-18 A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in development
- 2020-06-17 LIDDS publishes prospectus in connection with forthcoming rights issue
- 2020-03-05 LIDDS will participate in Redeye’s Fight Cancer Seminar on March 10
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
